Skip to main content


Showing posts with the label FDA

Breakthrough or Breakdown? Aducanumab’s Approval by the FDA with Comments from Neurologist Dr. Allan Levey

Aduhelm Puts Patients At The Helm, But At What Cost?

Alzheimer’s Disease and the FDA: Two Things To Watch

CBD for Your Anxiety: Ethical Concerns

Consumer Neurotechnology: New Products, More Regulatory Complexity

Brain devices: Navigating collaborations between industry, government, and researchers

Predicting Alzheimer’s Disease: Potential Ethical, Legal, and Social Consequences

The Army’s on Ecstasy: Marching toward an ethical drug policy

Emory Neuroethics on Facebook